"Gilead is looking to get the candidate approved in combination with ribavirin (:RBV) as an all-oral therapy for treating patients affected with genotypes 2 and 3 of the disease. The NDA also includes data backing the use of sofosbuvir in combination with RBV and pegylated interferon (peg-IFN) as a first-line therapy in patients suffering from the genotypes 1, 4, 5 and 6 of the virus."
Encouraging? It's amazing how duped the market has been re Gilead's "holy grail" all-oral 7977. Gen 2 and 3 are easy-to-treat genotypes. And yes, there it's all oral. It's Gen 1 that's tough to treat. And does anyone notice the term "peg-IFN" below to treat Gen 1? Not all oral people! Hats off to Gilead's press release folks. They've easily made their $11 billion back in market cap alone because of hype, they don't even need 7977.